TrialCompass™ TCL
Back to trials
Phase 2RecruitingPriority 2 · High priorityNCT06580002

Repurposing Riluzole for Cancer-Related Cognitive Impairment: A Pilot Trial

ClinicalTrials.gov

Plain-language summary

This trial is testing Riluzole for patients with cutaneous T-cell lymphoma (CTCL), including mycosis fungoides or Sézary syndrome at various stages of their disease. This is a Phase 2 trial, which means researchers are studying how well the treatment works and monitoring for side effects. Patients are randomly assigned to treatment groups, and neither patients nor doctors know which treatment is being given. This trial is available at 1 location in the United States. The trial is currently recruiting patients.

Who can join (key eligibility)

  • Age 18 Years or older
  • See full trial listing for complete eligibility

Final eligibility is determined by the trial team. This list is a starting point only.

What's being tested

Riluzole (DRUG): Given PO | Placebo (DRUG): Given PO

  • Riluzole, Placebo

Treatment length
Ask the trial team for details
Visit frequency
Ask the trial team for details

Learn more

What is CTCL?

Plain-language overview of CTCL plus all curated trials for this subtype.

Use our AI Assistant

Ask questions about this trial, eligibility, or T-cell lymphoma in general.

Generate a letter for your doctor

Create a printable letter to discuss this trial with your oncologist.

TrialCompass — Clinical Trial Summary

Repurposing Riluzole for Cancer-Related Cognitive Impairment: A Pilot Trial

NCT06580002

Phase: Phase 2 | Status: Recruiting | Priority: High

Plain-language summary

This trial is testing Riluzole for patients with cutaneous T-cell lymphoma (CTCL), including mycosis fungoides or Sézary syndrome at various stages of their disease. This is a Phase 2 trial, which means researchers are studying how well the treatment works and monitoring for side effects. Patients are randomly assigned to treatment groups, and neither patients nor doctors know which treatment is being given. This trial is available at 1 location in the United States. The trial is currently recruiting patients.

Who can join

  • Age 18 Years or older
  • See full trial listing for complete eligibility

What's being tested

Riluzole (DRUG): Given PO | Placebo (DRUG): Given PO

Drugs / treatments: Riluzole, Placebo

Treatment length: Ask the trial team for details

Visit frequency: Ask the trial team for details

Trial design

Randomized, double blind

Enrollment target: 75 patients

Primary endpoint: Change in circulating Brain-Derived Neurotrophic Factor (BDNF) levels over time in cancer survivors experiencing cognitive impairment (CRCI)

Ages: 18 Years to —

Start date: 2024-12-02 | Est. completion: 2027-12

Locations

1 US sites · 1 total

California

Contact

Chao Family Comprehensive Cancer Center University of California, Irvine | ucstudy@uci.edu | 1-877-827-8839

Sponsor: University of California, Irvine (OTHER)

Tags

CTCL · any

View on ClinicalTrials.gov

https://clinicaltrials.gov/study/NCT06580002

Prepared using TrialCompass (trialcompass.com) on August 2, 2026. For informational purposes only. Always discuss with your healthcare team.